A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy
Abstract Aldosterone antagonists slow the progression of chronic kidney disease (CKD), but their use is limited by hyperkalemia, especially when associated with RAS inhibitors.We examined the MaxFlo I Parts renoprotective effects of Ly, a novel non-steroidal mineralocorticoid receptor (MR) blocker, through two experimental protocols: In Protocol 1,